| # | Name | Description | Category | Type | Source | Website |
|---|
| # | Opportunity | Type | Region / Country | Amount | Deadline | Source |
|---|---|---|---|---|---|---|
| 76 | Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional) The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of me... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD |
||||||
| 77 | Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional) The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of me... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advanceadavnce mechanistic understanding of both biobehavioral and neurobiologfical pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. |
||||||
| 78 | Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes e... | Grant Cash Grant | United States | Award ceiling: $200,000 | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research. |
||||||
| 79 | Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional) Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and t... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and those aging with the illness, the mechanisms underlying the generation and trajectory of the illness remain poorly understood. The purpose of this initiative is to advance translational research to better understand the emergence and trajectory of schizophrenia and related disorders in mid to late life, and to identity targets for future development of prevention and treatment efforts. |
||||||
| 80 | Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional) This initiative seeks to solicit applications for research projects that address the link between social disconnection including b... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
This initiative seeks to solicit applications for research projects that address the link between social disconnection including both objective social isolation as well as perceived social isolation (otherwise known as loneliness) and suicide in late-life. Emphasis is placed on research that identifies neurobiological and environmental mechanisms associated with social isolation and loneliness that increase risk for suicidal thoughts and behavior in late-life, that uses an experimental therapeutics approach to identify targets and develop and test interventions to prevent late-life suicide, and that develops new and modifies existing service delivery models to enhance social connection in late-life to prevent suicide. |
||||||
| 81 | Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed) This Notice of Funding Opportunity (NOFO) encourages research on the biology of high confidence risk factors associated with compl... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
This Notice of Funding Opportunity (NOFO) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this NOFO, the term complex can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to model disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic ta... |
||||||
| 82 | Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand... | Grant Cash Grant | United States | Award ceiling: $499,000 | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this NOFO, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally |
||||||
| 83 | Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for identification of... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for identification of small molecules that function to elucidate the biology of disease as chemical probes or function as agonists or antagonists of disease target(s) for therapy or immunotherapy. The NOFO is intended to support discovery research for the identification of validated hits relevant to health-related outcomes of participating NIH Institutes. Stages of discovery research covered by this NOFO include: 1) assay development for specific biological targets and disease mechanisms relevant to the mission of participating NIH Institutes with the intent to screen for small molecule compounds that show potential as probes for use in advancing knowledge about the known targets, identifying new targets, or as pre-therapeutic leads; 2) screen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches to identify initial screening hits; 3) hit validation, including implementation of secondary assays that are orthogonal to the primary assay, advanced cheminformatics analysis and initial medicinal chemistry inspection to prioritize the hit set, and follow-up assays to characterize mode and mechanism of action of the validated hits; 4) hit-to-lead optimization, including SAR to optimize target engagement, selectivity and to minimize chemical liabilities, ADME, PK and PD studies, and, if appropriate, in vivo modeling to test efficacy or biological effects. |
||||||
| 84 | Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed) This Notice of Funding Opportunity (NOFO) encourages research on the biology of high-confidence risk factors associated with compl... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
This Notice of Funding Opportunity (NOFO) encourages research on the biology of high-confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular, and circuit substrates of neural function. For the purposes of this NOFO, the term complex can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular, and circuit mechanisms, these are neither required nor expected. Studies should not attempt to model disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components, and processes. The resulting paradigms, component pathways, and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic... |
||||||
| 85 | Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional) This initiative seeks to solicit applications for research projects that address the link between social disconnection including b... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
This initiative seeks to solicit applications for research projects that address the link between social disconnection including both objective social isolation as well as perceived social isolation (otherwise known as loneliness) and suicide in late-life. Emphasis is placed on research that identifies neurobiological and environmental mechanisms associated with social isolation and loneliness that increase risk for suicidal thoughts and behavior in late-life, that uses an experimental therapeutics approach to identify targets and develop and test interventions to prevent late-life suicide, and that develops new and modifies existing service delivery models to enhance social connection in late-life to prevent suicide. |
||||||
| 86 | Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional) Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and t... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and those aging with the illness, the mechanisms underlying the generation and trajectory of the illness remain poorly understood. The purpose of this initiative is to advance translational research to better understand the emergence and trajectory of schizophrenia and related disorders in mid to late life, and to identity targets for future development of prevention and treatment efforts. |
||||||
| 87 | Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes e... | Grant Cash Grant | United States | Award ceiling: $350,000 | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research. |
||||||
| 88 | Alcohol Health Services Research (R01 Clinical Trial Optional) The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing... | Grant Cash Grant | United States | Award ceiling: $500,000 | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations. |
||||||
| 89 | Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required) The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing... | Grant Cash Grant | United States | Award ceiling: $500,000 | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery. |
||||||
| 90 | Alcohol Health Services Research (R34 Clinical Trial Optional) The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations. |
||||||
| 91 | Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required) The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations. |
||||||
| 92 | Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed) The goal of this NOFO is to support doctoral candidates from a variety of academic disciplines for up to two years for the complet... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 7, 2026 Open | Grants.gov |
|
Source description
The goal of this NOFO is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with NIDA funding priorities detailed here (https://www.drugabuse.gov/funding/funding-priorities). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. |
||||||
| 93 | NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Not Allowed) This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Researc... | Grant Mixed | United States | Not provided on the source page. Please check the official source. | Open Sep 18, 2026 Open | Grants.gov |
|
Source description
This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial and other human subject research study results through accrual in a variety of community settings. The purpose of NCORP is to engage cancer patient populations, those at risk of cancer, and organizations in rigorous studies focused on cancer control, prevention, treatment and care delivery.NCORP is a community-based research network that:Designs and conducts clinical trials and other human subject studies for adults and children in cancer control, prevention, screening, and care delivery, as well as quality-of-life studies embedded within treatment trials;Enhances patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN)NCORP will support the following components that will be individually awarded through the respective Request for Applications (RFAs) indicated below:NCORP Research Bases (UG1 Clinical Trials Required);NCORP Community Sites (UG1 Clinical Trials Not Allowed)(covered by this NOFO); andNCORP Academic Community Sites (UG1 Clinical Trials Not Allowed).The NCORP Community Sites is a healthcare system, a consortium of healthcare systems, or a consortia of community hospitals and/or oncology practices, public hospitals, and/or health care centers that can enhance the representativeness of participants accrued to cancer control, prevention, treatment and care delivery clinical tri... |
||||||
| 94 | NCI Community Oncology Research Program (NCORP) Academic Community Sites (UG1 Clinical Trials Not Allowed) This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Researc... | Grant Mixed | United States | Not provided on the source page. Please check the official source. | Open Sep 18, 2026 Open | Grants.gov |
|
Source description
This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial and other human subject research study results through accrual in a variety of community settings. The purpose of NCORP is to engage cancer patient populations, those at risk of cancer, and organizations in rigorous studies focused on cancer control, prevention, treatment and care delivery.NCORP is a community-based research network that:Designs and conducts clinical trials and other human subject studies for adults and children in cancer control, prevention, screening, and care delivery, as well as quality-of-life studies embedded within treatment trials;Enhances patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN);NCORP will support the following components that will be individually awarded through the respective Request for Applications (RFAs) indicated below:NCORP Research Bases (UG1 Clinical Trials Required);NCORP Community Sites (UG1 Clinical Trials Not Allowed); andNCORP Academic Community Sites (UG1 Clinical Trials Not Allowed)(covered by this NOFO)NCORP Academic Community Sites are a consortium led by an academic center with a network of community hospitals and/or oncology practices, public hospitals, and/ or other healthcare centers that serve a patient population that can enhance the representativeness of participants accrued to cancer control, prevention, treatment and.... |
||||||
| 95 | NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required) This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Researc... | Grant Mixed | United States | Not provided on the source page. Please check the official source. | Open Sep 18, 2026 Open | Grants.gov |
|
Source description
This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial and other human subject research study results through accrual in a variety of community settings. The purpose of NCORP is to engage cancer patient populations, those at risk of cancer, and organizations in rigorous studies focused on cancer control, prevention, treatment and care delivery.NCORP is a community-based research network that:Designs and conducts clinical trials and other human subject studies for adults and children in cancer control, prevention, screening, and care delivery, as well as quality-of-life studies embedded within treatment trials;Enhances patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN);NCORP will support the following components that will be individually awarded through the respective Request for Applications (RFAs) indicated below:NCORP Research Bases (UG1 Clinical Trials Required)(covered by this NOFO);NCORP Community Sites (UG1 Clinical Trials Not Allowed); andNCORP Academic Community Sites (UG1 Clinical Trials Not Allowed).NCORP Research Bases will serve as the program's research hubs and are expected to:Provide an established organizational structure, with scientific and statistical leadership for developing, implementing, and analyzing multi-institutional cancer control, prevention, and care delivery (CCP&CD) clinical research, as well as qualit... |
||||||
| 96 | Limited Competition: National Primate Research Centers (P51) (Clinical Trials Not Allowed) This funding opportunity announcement (FOA) encourages grant applications that support the activities of the National Primate Rese... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 25, 2026 Open | Grants.gov |
|
Source description
This funding opportunity announcement (FOA) encourages grant applications that support the activities of the National Primate Research Centers (NPRCs). Nonhuman primates (NHPs) are most closely related to humans, both physiologically and genetically. Therefore, NHPs are critical animal models for basic and translational research aimed at understanding human biology, both in normal and diseased states. Proper husbandry and management of NHPs require specialized physical and intellectual resources, which are most effectively and economically provided in centralized primate centers, the resources of which are made available to investigators on a national basis. The NPRCs provide these resources to investigators/grantees who utilize NHPs in biomedical research and thereby complement and help enable the missions of the NIH Institutes and Centers. |
||||||
| 97 | Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required) Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites applications for P50 Research Cen... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 25, 2026 Open | Grants.gov |
|
Source description
Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. For the purpose of this FOA, a group of highly related cancers are those that are derived from the same organ system, such as gastrointestinal, neuroendocrine, head and neck, and other cancers. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers promoted and sustained by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant. |
||||||
| 98 | NHLBI Program Project Applications (P01 Clinical Trials Optional) The National Heart, Lung, and Blood Institute (NHLBI) Program Project Grant (P01) supports research related to fundamental process... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 25, 2026 Open | Grants.gov |
|
Source description
The National Heart, Lung, and Blood Institute (NHLBI) Program Project Grant (P01) supports research related to fundamental processes and diseases of the heart, blood and lymphatic vessels, lungs, and blood, including transfusion medicine, blood resources, and sleep disorders other programs including implementation science, health disparities, and translation research that address the mission of the Institute. This FOA requires a minimum of three interrelated research projects that investigate a complex biomedical theme or research question. The projects may be supported by core units, if justified, to facilitate economy of effort, space, and equipment. The NHLBI provides support for Program Project Grants (PPGs) in the belief that collaborative research efforts can accelerate the acquisition of knowledge more effectively than a simple aggregate of research projects that have no interaction or thematic integration. NHLBI is particularly interested in encouraging new scientific directions in PPGs. Use of the P01 activity code is viewed as an opportunity to attract scientists who have not traditionally been supported by the NHLBI. Further, the PPG environment presents an opportunity for emerging scientific leaders to gain insight into how to lead a successful scientific Program, and applicants will have the opportunity to include a project led by an Early Stage Investigator (ESI). All projects in the Program must be interrelated and have objectives that address a central theme within the scientific mandate of the NHLBI. |
||||||
| 99 | National Institute of General Medical Sciences Predoctoral Basic Biomedical Sciences Research Training Program (T32) The goal of the NIGMS Predoctoral Basic Biomedical Sciences Research Training Program is to develop a pool of well-trained scienti... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 25, 2026 Open | Grants.gov |
|
Source description
The goal of the NIGMS Predoctoral Basic Biomedical Sciences Research Training Program is to develop a pool of well-trained scientists available to address the Nations biomedical research agenda. Specifically, this funding opportunity announcement provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical graduate training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. |
||||||
| 100 | Alcohol Research-Related Resource Award (R24 Clinical Trial Not Allowed) The purpose of the Resource-Related Research Projects (R24) grant is to support investigator-initiated resources designed to provi... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Sep 25, 2026 Open | Grants.gov |
|
Source description
The purpose of the Resource-Related Research Projects (R24) grant is to support investigator-initiated resources designed to provide materials and services to support and advance biomedical research on a national basis. An R24 resource grant mechanism is a non-hypothesis-driven activity to provide data, materials, tools, or services that are essential to making timely, high quality, and cost-efficient progress in a field. Hypothesis-driven research applications should not be submitted in response to this program announcement but to another mechanism that encourages this type of research. The resource should be available to any qualified investigator, and should be highly quality controlled, and not duplicate resources available commercially or through other sources. Resources should be designed to provide services to the broad alcohol research community and should not be limited by any specific regional focus. |
||||||